Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tharimmune, Inc. - Common Stock (NQ: THAR )

2.560 -0.050 (-1.92%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tharimmune, Inc. - Common Stock

< Previous 1 2 Next >
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Via ACCESSWIRE
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Via ACCESSWIRE
Tharimmune Announces Upcoming Conference Presentations
Via ACCESSWIRE
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
Tharimmune Announces Upcoming Conference Presentations
Via ACCESSWIRE
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
Via ACCESSWIRE
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Via ACCESSWIRE
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Via ACCESSWIRE
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
Via ACCESSWIRE
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Via ACCESSWIRE
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Via ACCESSWIRE
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
Via ACCESSWIRE
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
Via ACCESSWIRE
Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
Via ACCESSWIRE
Tharimmune Announces $2.08 Million Private Placement
Via ACCESSWIRE
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
Tharimmune to Present at 2024 BIO International Convention
Via ACCESSWIRE
Tharimmune Announces 1-for-15 Reverse Stock Split
Via ACCESSWIRE
Tharimmune, Inc. (NASDAQ: THAR) Featured in Coverage of the EF Hutton Annual Global Conference
Via Investor Brand Network
Tharimmune To Participate in Two Upcoming Investor Conferences in May
Via ACCESSWIRE
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Via ACCESSWIRE
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Via ACCESSWIRE
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
Via ACCESSWIRE
Tharimmune, Inc. Announces Closing of $11 Million Public Offering
Via ACCESSWIRE
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... 
Via Newsfile
BioMedNewsBreaks – Tharimmune Inc. (NASDAQ: THAR) Announces Pricing of $10M Public Offering
Via Investor Brand Network
Tharimmune, Inc. Announces Pricing of $10 Million Public Offering
Via ACCESSWIRE
Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.